Relmada Therapeutics (NASDAQ:RLMD) Shares Down 3.3%

Relmada Therapeutics, Inc. (NASDAQ:RLMD)’s stock price traded down 3.3% during mid-day trading on Monday . The stock traded as low as $3.70 and last traded at $3.87. 178,113 shares traded hands during mid-day trading, a decline of 30% from the average session volume of 254,496 shares. The stock had previously closed at $4.00.

Relmada Therapeutics Price Performance

The stock has a market cap of $116.76 million, a P/E ratio of -1.18 and a beta of 0.19. The business’s 50 day simple moving average is $5.23 and its 200 day simple moving average is $3.98.

Relmada Therapeutics (NASDAQ:RLMD) last posted its earnings results on Tuesday, March 19th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.04. Research analysts predict that Relmada Therapeutics, Inc. will post -3.53 earnings per share for the current year.

Insider Buying and Selling at Relmada Therapeutics

In related news, CEO Sergio Traversa purchased 27,460 shares of Relmada Therapeutics stock in a transaction that occurred on Wednesday, January 31st. The shares were acquired at an average price of $4.00 per share, for a total transaction of $109,840.00. Following the transaction, the chief executive officer now directly owns 244,024 shares in the company, valued at $976,096. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Sergio Traversa bought 27,460 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The stock was bought at an average cost of $4.00 per share, for a total transaction of $109,840.00. Following the transaction, the chief executive officer now owns 244,024 shares of the company’s stock, valued at $976,096. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Maged Shenouda bought 6,875 shares of the business’s stock in a transaction on Wednesday, January 31st. The stock was purchased at an average price of $4.06 per share, for a total transaction of $27,912.50. Following the completion of the acquisition, the chief financial officer now owns 34,903 shares of the company’s stock, valued at approximately $141,706.18. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 91,176 shares of company stock valued at $350,305. 13.50% of the stock is currently owned by company insiders.

Institutional Trading of Relmada Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of RLMD. Stratos Wealth Partners LTD. bought a new position in shares of Relmada Therapeutics during the third quarter worth about $48,000. TD Asset Management Inc raised its stake in shares of Relmada Therapeutics by 100.0% during the 3rd quarter. TD Asset Management Inc now owns 25,000 shares of the company’s stock worth $75,000 after purchasing an additional 12,500 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in Relmada Therapeutics during the fourth quarter worth $243,000. Silverarc Capital Management LLC acquired a new stake in Relmada Therapeutics in the third quarter valued at $300,000. Finally, Vestal Point Capital LP bought a new position in shares of Relmada Therapeutics in the 4th quarter valued at about $476,000. Institutional investors and hedge funds own 45.24% of the company’s stock.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.